Kinase Inhibitors Translate Lab Discoveries into Exciting New Cures for Cancers

Overview

Journal Indian J Pediatr

Specialty Pediatrics

Date 2004 Sep 4

PMID 15345872

Citations 2

Authors

Mani Mohindru

Amit Verma

Affiliations

Soon will be listed here.

Abstract

Genetic mutations can lead to abnormal activation of certain kinases that in turn lead to excessive cell division seen in cancers. Inhibitors of over activated kinases can theoretically inhibit cancer causing pathways and result in tumor shrinkage. These discoveries have sparked a revolution in drug discovery with many small molecule kinases inhibitors now being used in cancer clinical trials. The amazing success of Imatinib, a blocker of the bcr-abl kinase in chronic myeloid leukemia has shown that the drugs based on these strategies can improve cure rates in cancer. In this article, the authors review the concepts of kinase inhibition in cancer and principles behind the success of imitanib. The authors also review other promising kinase inhibitors being used in clinical trials that are expected to aid the fight against cancer.

Citing Articles

Peptide-based fluorescent sensors of protein kinase activity: design and applications.

Sharma V, Wang Q, Lawrence D Biochim Biophys Acta. 2007; 1784(1):94-9.

PMID: 17881302 PMC: 2684651. DOI: 10.1016/j.bbapap.2007.07.016.

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue).

Mencher S, Wang L BMC Clin Pharmacol. 2005; 5:3.

PMID: 15854222 PMC: 1090568. DOI: 10.1186/1472-6904-5-3.

References

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

Donato N, Wu J, Stapley J, Gallick G, Lin H, Arlinghaus R . BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003; 101(2):690-8. DOI: 10.1182/blood.V101.2.690. View

Kelly K, Averbuch S . Gefitinib: phase II and III results in advanced non-small cell lung cancer. Semin Oncol. 2004; 31(1 Suppl 1):93-9. DOI: 10.1053/j.seminoncol.2003.12.020. View

Talpaz M, Silver R, Druker B, Goldman J, Gambacorti-Passerini C, Guilhot F . Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99(6):1928-37. DOI: 10.1182/blood.v99.6.1928. View

Levis M, Allebach J, Tse K, Zheng R, Baldwin B, Smith B . A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002; 99(11):3885-91. DOI: 10.1182/blood.v99.11.3885. View

Apperley J, Gardembas M, Melo J, Russell-Jones R, Bain B, Baxter E . Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002; 347(7):481-7. DOI: 10.1056/NEJMoa020150. View

Gambacorti-Passerini C, Gunby R, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003; 4(2):75-85. DOI: 10.1016/s1470-2045(03)00979-3. View

Goldman J . Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. Semin Hematol. 2003; 40(1 Suppl 1):10-7. DOI: 10.1053/shem.2003.50028. View

10.

Gilliland D, Griffin J . The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002; 100(5):1532-42. DOI: 10.1182/blood-2002-02-0492. View

11.

Grunwald V, Hidalgo M . Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003; 95(12):851-67. DOI: 10.1093/jnci/95.12.851. View

12.

Demetri G, von Mehren M, Blanke C, Van Den Abbeele A, Eisenberg B, Roberts P . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7):472-80. DOI: 10.1056/NEJMoa020461. View

13.

Garber K . Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure. J Natl Cancer Inst. 2003; 95(14):1036-8. DOI: 10.1093/jnci/95.14.1036. View

14.

Weisberg E, Griffin J . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000; 95(11):3498-505. View

15.

Shawver L, Slamon D, Ullrich A . Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002; 1(2):117-23. DOI: 10.1016/s1535-6108(02)00039-9. View

16.

Blagosklonny M . STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia. 2002; 16(4):570-2. DOI: 10.1038/sj.leu.2402409. View

17.

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346(9):645-52. DOI: 10.1056/NEJMoa011573. View

18.

Ciardiello F, De Vita F, Orditura M, De Placido S, Tortora G . Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opin Emerg Drugs. 2003; 8(2):501-14. DOI: 10.1517/14728214.8.2.501. View

19.

Propper D, McDonald A, Man A, Thavasu P, Balkwill F, Braybrooke J . Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001; 19(5):1485-92. DOI: 10.1200/JCO.2001.19.5.1485. View

20.

Herbst R, Giaccone G, Schiller J, Natale R, Miller V, Manegold C . Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004; 22(5):785-94. DOI: 10.1200/JCO.2004.07.215. View